Global Reach Intas operates in 85+ countries with a robust global subsidiary network (Accord Healthcare) spanning EU, US, Canada, SA, Australia, APAC, CIS, and MENA, presenting numerous cross-border selling opportunities for formulations, generics, and biosimilars.

Biosimilars Growth EU-GMP certified biopharma division focused on affordable biosimilars across oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone therapies, signaling a strong entry point for partnerships, licensing, and co-development in high-value biologics.

R&D Investment Significant R&D focus with 6-7% of revenue allocated to innovation and a pipeline of 300+ high-value products including FTF/FTM, biosimilars, and NDDS, offering opportunities for joint development deals, technology licensing, and early access programs.

Manufacturing Scale 17 advanced facilities with WHO-GMP/USFDA/EMA accreditations and a dedicated Plasma Fractionation unit, enabling scalable contract manufacturing, co-packaging, and supply arrangements for global partners seeking reliable production capacity.

Regulatory & Compliance Recent regulatory tensions such as FDA warning in 2026 highlight quality and data integrity risk areas, suggesting a sales angle around quality enhancement services, regulatory consulting partnerships, and GMP/compliance improvement collaborations to restore trust.